On July7, 2021, Shanghai Aurisco Biotechnology Co., Ltd., with aninvestment of RMB 60 million by Aurisco Pharmaceutical Co.,Ltd., was formally established to provide customers around the worldwith nucleic acid drugs from laboratory research and development, processdevelopment, and clinical stage productionto commercialized one-stop service. The establishment ofShanghai Aurisco Biotechnology Co., Ltd. is a symbol that Aurisco utilizes itsown strength and capital market advantagesto deploy ahead of schedule and enter the nucleic aciddrug industry. It will further accelerate Aurisco's industrial upgrading,improve corporate competitiveness, and achieve the company's strategicgoal of sustainable development, also improve the company's economicbenefits.
Thelegal representative of Shanghai Aurisco Biotechnology Co., Ltd. isDr. Jinliang Li.